sábado, 10 de febrero de 2018

FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. | AHRQ Patient Safety Network

FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. | AHRQ Patient Safety Network

PSNet email header



  • Press Release/Announcement
  •  
  • Published January 2018

FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older.

    Addressing the opioid epidemic has necessitated new approaches to prevent opioid misuse. This announcement describes new FDA requirements regarding labeling changes for prescription cough and cold medicines containing codeine or hydrocodone in pediatric patients.














    View More

    No hay comentarios: